Arylsulfone-based HIV-1 non-nucleoside reverse transcriptase inhibitors.

Valeria Famiglini (1) , Antonio Coluccia (1) , Andrea Brancale (2) , Sveva Pelliccia (1) , Giuseppe La Regina (1) , Romano Silvestri (1)

1 Department of Medicinal Chemistry and Technologies
2 Welsh School of Pharmacy

HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs) represent one of the most significant classes of drugs for the treatment of AIDS/HIV infection. Over the past two decades several potent arylsulfone-based HIV-1 NNRTIs and related analogs have been developed. This review provides an essential overview of the structure-activity relationships of the arylsulfone-based HIV-1 NNRTIs. Furthermore, structural information useful for the design and development of new sulfur containing NNRTIs with enhanced antiretroviral activity against HIV-1 wild type and clinically relevant drug resistant HIV-1 mutant strains will be discussed.

Domaines: Pharmacologie

Valeria Famiglini, Antonio Coluccia, Andrea Brancale, Sveva Pelliccia, Giuseppe La Regina, et al.. Arylsulfone-based HIV-1 non-nucleoside reverse transcriptase inhibitors.. Future Medicinal Chemistry, 2013, 5 (18), pp.2141-56. ⟨10.4155/fmc.13.174⟩. ⟨pasteur-01054201⟩